Document Detail

The association between calcium channel blocker use and prostate cancer outcome.
MedLine Citation:
PMID:  23280547     Owner:  NLM     Status:  Publisher    
BACKGROUND: Epidemiological studies indicate that calcium channel blocker (CCB) use is inversely related to prostate cancer (PCa) incidence. The association between CCB use and PCa aggressiveness at the time of radical prostatectomy (RP) and outcome after RP was examined. METHODS: Medication use, PCa aggressiveness and post-RP outcome were retrieved from a prospectively populated database that contains clinical and outcome for RP patients at Roswell Park Cancer Institute (RPCI) from 1993 to 2010. The database was queried for anti-hypertensive medication use at diagnosis for patients with ≥1 year follow-up. Recurrence was defined using NCCN guidelines. Chi-Square tests assessed the relationship between CCB use and PCa aggressiveness. Cox regression models compared the distribution of progression-free survival (PFS) and overall survival (OS) with adjustment for covariates. Results for association between CCB usage and PCa aggressiveness were validated using data from the population-based North Carolina-Louisiana Prostate Cancer Project (PCaP). RESULTS: 48%, 37%, and 15% of RPCI's RP patients (n = 875) had low, intermediate, and high aggressive PCa, respectively. 104 (11%) had a history of CCB use. Patients taking CCBs were more likely to be older, have a higher BMI and use additional anti-hypertensive medications. Diagnostic PSA levels, PCa aggressiveness, and margin status were similar for CCB users and non-users. PFS and OS did not differ between the two groups. Tumor aggressiveness was associated with PFS. CCB use in the PCaP study population was not associated with PCa aggressiveness. CONCLUSIONS: CCB use is not associated with PCa aggressiveness at diagnosis, PFS or OS. Prostate © 2012 Wiley Periodicals, Inc.
Michael A Poch; Diana Mehedint; Dawn J Green; Rochelle Payne-Ondracek; Elizabeth T H Fontham; Jeannette T Bensen; Kristopher Attwood; Gregory E Wilding; Khurshid A Guru; Willie Underwood; James L Mohler; Hannelore V Heemers
Related Documents :
23564027 - Association between helicobacter pylori infection and liver cancer mortality in 67 rura...
24151357 - Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted the...
23500637 - Prostate cancer: how do patients choose their treatment?
24739047 - Wage specific assessment of mammography screening in brazilian women.
15154627 - Longitudinal changes in serum her-2/neu oncoprotein levels in trastuzumab-treated metas...
22321727 - Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-31
Journal Detail:
Title:  The Prostate     Volume:  -     ISSN:  1097-0045     ISO Abbreviation:  Prostate     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2013-1-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8101368     Medline TA:  Prostate     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
Department of Urology, Roswell Park Cancer Institute, Buffalo, New York.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer - investigation of a ...
Next Document:  Hybrid Mechanoresponsive Polymer Wires Under Force Activation.